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Diabeteksen on havaittu olevan yhteydessä matalampaan riskiin sairastua eturauhassyöpään (PCa), 
mutta yhteys huonosti erilaistuneeseen, ns. high-grade -syöpään on epäselvä. Hyperglykemian 
merkitys eturauhassyövän riskitekijänä on niin ikään epäselvä. 
Tutkimuksen tavoitteena oli arvioida yleistä eturauhassyöpäriskiä, sekä riskiä sairastua 
pahanlaatuisempaan (Gleason-luokitus 7-10) ja levinneeseen (TNM-luokituksen M1) syöpään 
miehillä, joiden paastoverensokeriarvot olivat diabeettisella tasolla. 
Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) -tutkimukseen 
osallistuneiden miesten tiedot yhdistetiin paastoverensokeriarvojen mittaustulosten saamiseksi 
Fimlab-laboratorion tietokantaan. Verensokerimittausten tietoja oli saatavilla 17 860:lle miehelle, 
alkaen vuodesta 1978. Mittaustulosten perusteella jokaiselle miehelle laskettiin keskimääräinen 
vuosittainen verensokeritaso, ja heidät luokiteltiin verensokeritasoltaan joko normoglykeemisiksi, 
prediabeettisiksi tai diabeettisiksi. Seuranta alkoi FinRSPC-tutkimuksen alusta 1996–1999, ja jatkui 
eturauhassyöpädiagnoosiin, kuolemaan tai vuoden 2014 loppuun asti. 
Tutkimuksen tilastollisessa analyysissä käytetiin Coxin regressiomallia, joka oli vakioitu iän, 
FinRSPC-tutkimusen satunnaistamisen, sekä eri lääkkeiden (statiinit, verenpainelääkkeet, 
tulehduskipulääkkeet, aspiriini, 5-alfa-reduktaasi-inhibiittorilääkiitys, alfasalpaajat sekä diabeteksen 
hoidossa käytetyt lääkkeet) suhteen. Analyysissä laskettiin riskiyhteyksien suhteet (HR) sekä 95 
%:n luottamusvälit (CI) kokonaiseturauhassyöpäriskille, sekä erikseen Gleason 6-, Gleason 7-10-, 
paikallisille sekä levinneille syöville. 
Tutkimuksen mediaani seuranta-aika oli 14,7 vuotta. Seurannan aikana diagnosoitiin yhteensä 1 663 
uutta eturauhassyöpätapausta. Normoglykeemisiin miehiin verrattuna diabeettisen verensokeritason 
omaavien miesten riski sairastua eturauhassyöpään oli kohonnut (HR 1.52; 95 % CI 1.31-1.75). 
Riskin kohoaminen oli havaittavissa riippumatta kasvaimen Gleason-luokituksesta. Kohonnut riski 
oli yhteydessä kymmenen vuotta aikaisemmin koholla olleeseen verensokeritasoon (HR 1.34; 95 % 
CI 0.93-1.93). Diabeteksen hoitoon käytettävien lääkkeiden käyttö palautti riskin 
normoglykeemisten miesten tasolle.  
Miehet, joiden paastoverensokeriarvot ovat diabeettisella tasolla, ovat suuremmassa riskissä 
sairastua eturauhassyöpään. Tämä riskin suureneminen on ilmeisesti pitkäaikainen, sillä kohonnut 
paastoverensokeritaso noin kymmenen vuotta ennen eturauhassyöpädiagnoosia on yhteydessä riskin 
kohoamiseen. Diabeteksen hoitoon käytettävä lääkitys näyttää kuitenkin palauttavan riskin samalle 
tasolle kuin normoglykeemisillä miehillä.  
3 
 
CONTENTS 
 
1.  Abstract       4 
2.  Introduction      5 
3.  Materials and Methods     5 
3.1 Study Cohort      5 
3.2 Information on Blood Glucose Level and Glycated Hemoglobin   6 
3.3 Statistical Analysis      7 
4.  Results       8 
4.1 Population Characteristics     8 
4.2 Fasting Blood Glucose, Hba1c and Prostate Cancer Risk   10 
4.3 Effect Modification by Background Variables    10 
4.4 Role of Change in Fasting Glucose Levels After Initiation Of Antidiabetic Drug Use 10 
4.5 Long-Term Effects of Fasting Glucose Levels    11 
5.  Discussion      16 
6.  Funding       18 
7. Conflicts of interest      18 
8.  References      19
4 
 
1. ABSTRACT 
Background: Diabetes has been associated with lowered overall risk of prostate cancer (PCa), but 
the role of hyperglycemia as a PCa risk factor is unclear.  
Objective: To estimate PCa risk among men with diabetic fasting blood glucose level. 
Design, setting and participants: The study population of the Finnish Randomized Study of 
Screening for Prostate Cancer (FinRSPC) was linked to the regional laboratory database for 
information on fasting glucose measurements since 1978. The data was available for 17,860 men. 
Based on the average yearly glucose level men were categorized as normoglycemic, prediabetic or 
diabetic. Follow-up started at the FinRSPC baseline in 1996-1999 and continued until prostate 
cancer diagnosis, death, or the end of 2014. 
Outcome measurements and statistical analysis: Cox regression with adjustment for age, 
FinRSPC study arm and use of statins, antihypertensive drugs, NSAIDs, aspirin, 5α-reductase 
inhibitors and alpha-blockers was used to calculate hazard ratios (HRs) and 95% confidence 
intervals (95%CIs) for prostate cancer overall and separately for Gleason 6, Gleason 7-10, non-
metastatic and metastatic tumors. 
Results: During the median follow-up of 14.7 years a total of 1,663 new PCa cases were diagnosed. 
Compared to normoglycemic men, men with diabetic blood glucose level had increased risk of PCa 
(HR 1.52; 95% CI 1.31-1.75). The risk increase was observed for all tumor grades.  The risk 
increase persisted for a decade after the measurement. Use of antidiabetic drugs removed the risk 
association; p for difference < 0.001. Limitations include absence of information on lifestyle factors 
and limited information on BMI.  
Conclusions: Men with diabetic fasting blood glucose level have an increased prostate cancer risk. 
The risk increase is long-term, initiating approximately a decade before the diagnosis. Use of 
antidiabetic drugs attenuates the risk increase. 
Keywords: Prostate cancer; hyperglycaemia; glycemic control 
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2. INTRODUCTION 
The relationship between established type 2 diabetes mellitus (DM) and different types of cancer 
has been investigated broadly. Studies have shown that people with DM have lower risk of 
developing prostate cancer (PCa) compared with non-diabetics (1,2). However, it is not clear 
whether this concerns also poorly differentiated PCa, as some studies have suggested that the risk 
could be elevated (3). Glucose metabolism may have an independent role in prostate cancer 
development and progression (4,5). However, the mechanism behind the risk association between 
diabetes and PCa is unclear. There is evidence that hyperglycemia and poor glycemic control and 
the related hyperinsulinaemia could be the possible links (6-8). Yet there are very few studies 
concentrating on connections between PCa and blood glucose levels and glycemic control, and the 
results from available studies are conflicting. Some have reported increased risk of advanced or 
aggressive PCa among men with higher glucose levels (9), while other studies have reported a 
protective association between hyperglycemia and PCa (4,10).  
In this study we investigated the associations between fasting blood glucose and glycemic control 
(glycated hemoglobin, HbA1c) and PCa risk overall and by Gleason grade and tumor stage in a 
cohort of men participating in The Finnish Randomized Study of Screening for Prostate Cancer 
(11). 
 
 
3. MATERIALS AND METHODS 
 
3.1 Study cohort 
The Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) is the largest component 
of the multinational European Study of Prostate Cancer Screening (ERSPC) (12).  In the FinRSPC, 
all men aged 55-67 from Tampere and Helsinki residential areas were identified between 1996 and 
1999. After exclusion of prevalent prostate cancer cases identified from national Finnish Cancer 
Registry, a total of 80,144 men were randomly assigned either to be screened with PSA at four-year 
intervals (the screening arm, 31,866 men) or to control arm with no intervention and followed through 
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national registries (48,278 men). The screening finished in 2008, but the follow-up for cancer cases 
in this study extended until the end of 2014. The available information on prostate cancers were 
obtained trough study database or through The Finnish Cancer Registry for men in the control arm. 
The information included date of diagnosis, tumor Gleason score and tumor stage at diagnosis, 
recorded in this study as non-metastatic (all M0 cases) and metastatic (all M1 cases). 
The Finnish Cancer Registry is a nationwide registry collecting information of cancer diagnoses from 
all Finnish health care units and pathology laboratories through mandatory notifications. The registry 
covers more than 99% of all cancer cases diagnosed in Finland (13).  
To obtain information on BMI the participants of the third screening round during 2004-2008 were 
mailed surveys asking height and weight along with the screening invitations (14). This information 
was available for 11,698 men in the FinRSPC cohort. 
The study cohort was linked to a nationwide prescription database of the Social Insurance Institution 
(SII) of Finland. The SII is a governmental agency providing reimbursements for the cost of 
physician-prescribed drugs to all Finnish citizens. From this database we obtained information on 
usage of prescribed antidiabetic drugs, antihypertensive drugs, statins, NSAIDs and aspirin during 
1995-2009. Information on over-the-counter drug purchases or on drugs administered during hospital 
inpatient periods was not available. 
 
 
3.2 Information on blood glucose level and glycated haemoglobin 
The information on results from each measurement of fasting plasma or blood glucose level and 
glycated hemoglobin (HbA1c) performed at the Pirkanmaa region were obtained from the Fimlab 
database and linked to the study cohort by using individual identifier number. The data was available 
from 1978 for fasting blood glucose level and from 1991 for HbA1c. 
Fimlab Laboratories is one of the leading laboratory companies in Finland (15). Fimlab provides 
laboratory services, education and research in Pirkanmaa, Central Finland and Tavastia regions. A 
major part of laboratory measurements in the Pirkanmaa region are done in Fimlab laboratories. 
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The information on fasting glucose levels and HbA1c levels were available for 17,860 and 11,736 
men, respectively. Each measured fasting glucose level was divided into three categories: 
normoglycemic if fasting glucose level was under or equal to 6.0 mmol/l measured from plasma or 
under or equal to 5.5 mmol/l measured from blood; pre-diabetic if glucose level was between 6.0 and 
7.0 mmol/l (plasma) or between 5.6 and 6.1 mmol/l (blood) and diabetic if glucose level was over 7.0 
mmol/l (plasma) or over 6.1 mol/l (blood). The HbA1c levels were also divided into three categories: 
normoglycemic if HbA1c was under 39 mmol/mol or under 5.7%, prediabetic if HbA1c was between 
39 and 47mmol/mol or between 5.7 and 6.4%, and diabetic if HbA1c level was over 47mmol/mol or 
over 6.4%.  
 
 
3.3 Statistical analysis 
We used Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence 
intervals (CIs) for overall risk of prostate cancer by fasting glucose and HbA1c levels. Analyses for 
Gleason 6 or less, Gleason 7-10, non-metastatic and metastatic tumors were performed separately. 
The follow-up commenced from the FinRSPC randomization (baseline) and ended at the date of 
death, diagnosis of prostate cancer, emigration or end of the follow-up time (31 December 2014), 
whichever came first. The time axis was years and month since the baseline. The model was adjusted 
for age only (age-adjusted analysis) and further for the FinRSPC study arm and the use of 
antihypertensive drugs, cholesterol-lowering drugs, NSAIDs and aspirin (multivariable-adjusted 
model). 
For each calendar year we calculated the average yearly fasting glucose and HbA1c levels based on 
all measurements within that year. Fasting glucose level and HbA1c were analyzed as time-dependent 
variables, updated separately for each year after the baseline. 
We further calculated the average blood glucose levels both before and after initiation of antidiabetic 
drug use, i.e. the first recorded purchase of any antidiabetic drug. Fasting glucose level before and 
after antidiabetic drug use was analyzed as time-independent variables. 
The association between fasting glucose level and prostate cancer risk in subgroups was evaluated by 
repeating the analyses after stratifying the study population by background variables. We tested effect 
modification by adding an interaction term between blood glucose level and the effect modifier into 
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the Cox regression model. The interaction term was considered statistically significant if the p-value 
was ≤ 0.05. 
The temporal association between fasting glucose level and prostate cancer risk was evaluated by 
performing separate lag time analysis for measurements done ten and twenty years earlier. 
We used IBM SPSS statistics software (version 23) to perform Cox regression analyses. All p-values 
are two-sided.  
 
 
4. RESULTS 
4.1 Population characteristics 
Of the 17,860 men, 8,481 were normoglycemic, 5,812 were at the pre-diabetic range and 3,567 men 
were at the diabetic range of fasting glucose (Table 1). During the median follow-up of 14.7 years 
after the baseline, a total of 1,663 prostate cancers were diagnosed in the study cohort, 808 in the 
normoglycemic group, 454 in the pre-diabetic group and 401 in the diabetic group. Median BMI in 
the diabetic group was non-significantly higher compared to the normoglycemic group. 
The use of cholesterol-lowering drugs, antihypertensive drugs and aspirin was more common in the 
diabetic group compared to the normoglycemic or pre-diabetic group. However, use of NSAIDs and 
5α-reductase inhibitors was less common in the diabetic group (Table 1). 
Median PSA was lower among diabetic men in all three FinRSPC screening rounds compared to 
normoglycemic men (Table 1).  
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Table 1. Population characteristics. Study cohort of 17,860 men from the Finnish Randomized Study 
of Screening for Prostate Cancer with at least one fasting blood/plasma glucose measurement 
available during 1978-2014. 
 
 Average fasting blood glucose level during follow-up 
 Normoglycemic Pre-diabetic Diabetic 
n of men 8,481 5,812 3,567 
Median (IQR) follow-up 17.0 (15.1-18.0) 16.3 (13.8-18.0) 15.3 (7.1-17.0) 
n of PCa cases 808 454 401 
Gleason score; n (%)    
6 or less 409 (50.6) 215 (47.4) 203 (50.6) 
7-10 384 (47.5) 230 (50.7) 189 (47.1) 
Tumor stage; n (%)    
Localized 759 (93.9) 410 (90.3) 374 (93.3) 
Metastatic 48 (5.9) 44 (9.7) 25 (6.2) 
Median (IQR) PSA in    
1st screening round 1.02 (0.62-1.76) 0.97 (0.61-1.69) 1.01 (0.58-2.06)** 
2nd screening round 1.30 (0.77-2.28) 1.23 (0.72-2.26) 1.16 (0.66-2.31)** 
3rd screening round 1.43 (0.81-2.49) 1.39 (0.77-2.41) 1.19 (0.67-2.24))** 
Median (IQR) BMI 26.0 (24.2-28.3) 27.7 (25.3-30.6) 28.6 (26.2-31.6) 
Antidiabetic medication 
use; n(%)1 
207 (2.4) 1,370 (23.6)* 2,376 (66.6)* 
Cholesterol-lowering 
drug use; n(%) 
3,291 (38.8) 2,708 (46.6)* 1,851 (51.1)* 
Antihypertensive drug 
use; n (%) 
5,481 (64.6) 4,387 (75.5)* 2,917 (81.8)* 
NSAID use; n (%) 6,845 (80.7) 4,692 (80.7) 2,749 (77.0)* 
Aspirin use; n (%) 1,536 (18.1) 1,159 (19.9)* 715 (20.0)* 
5α-reductase inhibitor 
use; n (%) 
1,253 (14.8) 724 (12.5)* 384 (10.8)* 
 
* P < 0.05 compared to the normoglycemic group. Calculated with chi-square test. 
** P < 0.05 compared to the normoglycemic group. Calculated with Mann-Whitney U- test. 
1 Categorization based on average blood glucose level, thus also users of antidiabetic drugs may be 
included in the normoglycemic group if they have good blood glucose control  
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4.2 Fasting blood glucose, HbA1c and prostate cancer risk 
Compared to the normoglycemic men, overall PCa risk was elevated in diabetic, but not in pre-
diabetic men; multivariable adjusted HR 1.52; 95% CI 1.31-1.75 (Table 2). The risk was similarly 
elevated regardless of tumor Gleason score. However, the risk elevation was limited to non-metastatic 
tumors; fasting blood glucose level was not associated with risk of metastatic prostate cancer (Table 
2). Association between HbA1c levels and PCa risk was not statistically significant. However, the 
number of men in these analyses was low. 
 
 
4.3 Effect modification by background variables 
The connection between fasting glucose level and PCa risk was affected by several background 
variables (Figure 1a). Diabetic blood glucose level was associated with increased risk in the 
FinRSPC screening arm but not in the control arm (p for interaction < 0.001). The risk association 
was also modified by the use of antihypertensive drugs; the association was weaker in users of these 
drugs (p for interaction 0.018). Further, use of antidiabetic drugs abolished the risk association (p 
for interaction < 0.001).  
Similar risk modifications were observed also for Gleason score 8-10 tumors (Figure1b). However, 
the interactions were not statistically significant in this subgroup. 
 
 
4.4 Role of change in fasting glucose levels after initiation of antidiabetic drug 
use 
Changes in fasting blood glucose levels after the initiation of antidiabetic drug use were not associated 
with changes in prostate cancer risk (Table 3). Similarly, no change in prostate cancer risk was 
observed by changes in fasting glucose levels after initiation of metformin use. 
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4.5 Long-term effects of fasting glucose levels 
Blood glucose level measured 10 years earlier was borderline significantly associated with elevated 
PCa risk as in our main analysis; diabetic fasting glucose level was associated with increased risk of 
non-metastatic tumors and Gleason 6 or less tumor (Table 4). However, no risk associations were 
observed for the blood glucose levels measured two decades earlier.  
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Table 2. Prostate cancer risk by average fasting blood glucose and HbA1c level. Study cohort of 17,860 men from the Finnish Randomized Study of 
Screening for Prostate Cancer. 
 
 Prostate cancer risk 
 Overall Gleason 6 or less Gleason 7-10 Localized PCa Metastatic 
 HR (95% 
CI)age-adjusted 
HR (95% 
CI)multivar.-
adjusted 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multivar.-
adjusted 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multivar.-
adjusted 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multivar.-
adjusted 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multivar.-
adjusted 
Fasting blood glucose level          
Normal Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref 
Pre-
diabetic 
1.07  
(0.99-1.23) 
 
1.09  
(0.95-1.26) 
1.03 
(0.84-1.27) 
1.08  
(0.95-1.26) 
1.09 
(0.89-1.34) 
1.10 
(0.90-1.36) 
1.10 
(0.94-1.27) 
1.13 
(0.97-1.31) 
0.75  
(0.43-1.31) 
0.74  
(0.42-1.30) 
Diabetic 1.36 
(1.19-1.56) 
1.52 
(1.31-1.75) 
1.26 
(1.04-1.53) 
1.48  
(1.21-1.81) 
1.38 
(1-13-1.70) 
1.46 
(1.18-1.81) 
1.39  
(1.21-1.61) 
1.57 
(1.35-1.82) 
0.99  
(0.58-1.69) 
0.94 
(0.54-1.64) 
HbA1c level          
Normal Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref 
Pre-
diabetic 
1.13 
(0.88-1.44) 
1.15 
(0.90-1.47) 
1.07 
(0.75-1.54) 
1.11 
(0.77-1.59) 
1.17 
(0.83-1.64) 
1.18 
(0.84-1.66) 
1.13 
(0.87-1.46) 
1.16 
(0.89-1.50) 
1.05 
(0.42-2.62) 
1.08 
(0.43-2.70) 
Diabetic 0.95 
(0.73-1.23) 
1.04 
(0.80-1.35) 
0.77 
(0.53-1.13) 
0.89 
(0.60-1.31) 
1.08 
(0.75-1.53) 
1.11 
(0.77-1.59) 
0.87 
(0.67-1.15) 
0.96 
(0.73-1.26) 
1.77 
(0.73-4.30) 
1.83 
(0.74-4.52) 
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Figure 1. Association between prostate cancer risk and blood glucose level in subgroup analysis. Study cohort of 17,860 men from the Finnish 
Randomized Study of Screening for Prostate Cancer. 
 
a) Overall PCa risk 
 
 Pre-D = pre-diabetic, D = diabetic blood glucose level 
 *  P for interaction = 0.229 for pre-diabetic, p < 0.001 for diabetic men 
 ** P for interaction = 0.435 for pre-diabetic, p = 0.018 for diabetic men 
 *** P for interaction = 0.153 for pre-diabetic, p < 0.001 for diabetic men 
*** 
** 
* 
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b) Risk of Gleason 8-10 PCa 
 
 
 Pre-D = pre-diabetic, D = diabetic blood glucose level
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Table 3. Impact of change in fasting blood glucose level after initiation of antidiabetic drug use. Study 
cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer. 
  
 
 
 
 
 
 
 
 
 
 
Table 4. Association between the fasting blood glucose level 10 and 20 years earlier and prostate 
cancer risk. Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate 
Cancer. 
 
Prostate cancer risk 
 Overall Gleason 6 or 
less 
Gleason 7-10 Localized PCa Metastatic 
 
 HR (95% 
CI)multivar.-adjusted 
HR (95% 
CI)multivar.-adjusted 
HR (95% 
CI)multivar.-adjusted 
HR (95% 
CI)multivar.-adjusted 
HR (95% 
CI)multivar.-adjusted 
 
Average fasting blood glucose level 10 years earlier 
Normal Ref Ref Ref Ref Ref 
Pre-diabetic 1.27  
(0.78-1.90) 
0.63 
(0.26-1.52) 
1.70 
(0.98-2.92) 
1.16 
(0.73-1.86) 
1.97 
(0.44-8.82) 
Diabetic 1.34  
(0.93-1.93) 
1.62 
(0.97-2.69) 
1.31 
(0.67-1.91) 
1.41 
(0.97-2.04) 
0.38 
(0.04-3.42) 
Average fasting blood glucose level 20 years earlier 
Normal Ref Ref Ref Ref Ref 
Pre-diabetic 0.30 
(0.04-2.20) 
0.65 
(0.08-5.07) 
- 0.32 
(0.04-2.35) 
- 
Diabetic 0.97 
(0.41-2.32) 
- 1.78 
(0.68-4.67) 
0.90 
(0.36-2.26) 
1.51 
(0.15-37.8) 
 
Prostate cancer risk 
 Overall Gleason 6 or 
less 
Gleason 7-10 Localized 
PCa 
Metastatic 
 
 HR (95% 
CI)multivar.-adjusted 
HR (95% 
CI)multivar.-adjusted 
HR (95% 
CI)multivar.-adjusted 
HR (95% 
CI)multivar.-
adjusted 
HR (95% 
CI)multivar.-adjusted 
 
Change in fasting blood 
glucose level 
    
No change Ref Ref Ref Ref Ref 
Decrease 0.82  
(0.49-1.36) 
0.85 
(0.39-1.84) 
0.74 
(0.37-1.47) 
0.67 
(0.38-1.20) 
2.87 
(0.87-9.50) 
Increased 0.83 
(0.55-1.26) 
1.07 
(0.59-1.93) 
0.62 
(0.34-1.13) 
0.85 
(0.54-1.29) 
0.92 
(0.23-3.68) 
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5. DISCUSSION 
In this study we observed an association between fasting blood glucose level and elevated prostate 
cancer risk. This association was more noticeable in the screening arm, and concerned both poorly 
and well-differentiated cancers. Previous studies suggest that diabetes mellitus and use of 
antidiabetic drugs are associated with lowered overall prostate cancer risk, while the risk of high-
grade tumors may be elevated (16-19). Our findings do not support the risk lowering association for 
diabetes as a condition, as diabetic fasting blood glucose levels were associated with increased, not 
lowered prostate cancer risk. This supports role of hyperglycemia as prostate cancer risk factor. 
Nevertheless, use of antidiabetic drugs abolished the risk increase observed with diabetic fasting 
blood glucose level. Therefore our study indirectly supports anticancer effects of antidiabetic drugs, 
but the mechanism of action is probably unrelated to blood glucose levels.  
 
Some previous studies have reported association between diabetes and lowered PSA compared to 
non-diabetic men (20-22). Concordantly, median PSA was lower also in our study. This would 
presumably lead to lower incidence of PCa, as fewer prostate biopsies would be performed due to 
PSA elevation. In a setting of prostate cancer screening this would mean lower PCa incidence 
among diabetic men especially in the FinRSPC screening arm. In contrast, we observed a stronger 
association with increased PCa risk in the FinRSPC screening arm, which suggests that prostate 
cancer incidence among diabetic men is higher compared to non-diabetic men even if the median 
PSA is lower. The risk elevation seems to apply to all tumor grades as the risk elevation was 
observed also for high-grade tumors.  
 
A previous meta-analysis of 14 epidemiological studies found increased risk of several cancer types 
for elevated HbA1c, excluding prostate cancer (4). Concordantly, we did not observe risk 
associations with HbA1c, only with fasting blood glucose levels. 
 
Another previous study has examined the association between blood glucose and prostate cancer 
risk. (23). In this case-cohort study of 500 participants insulin concentrations and glucose 
concentrations were determined from a single overnight fasting serum sample 5 to 12 years before 
prostate cancer diagnosis. The study suggests an association between PCa risk and elevated fasting 
serum insulin, but not with elevated glucose levels. In contrast to our study, the observed blood 
glucose levels were mainly in the normal range, and no diabetic blood glucose levels were 
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observed. Thus our results are in concordance with this previous study, as we did not observe any 
risk increase even in men with pre-diabetic blood glucose level, only among men at diabetic glucose 
level. 
 
The significance of blood glucose as PCa risk factor is supported by our earlier findings in which 
we found connection between changes in genes associated to glucose metabolism and PCa risk (5). 
Previously reported lower PCa risk among men with diabetes could be explained by use of 
antidiabetic medication; for example lower PCa risk has been reported among metformin users (24-
27). In this study the use of antidiabetic drugs abolished the observed association between high 
blood glucose levels and elevated risk of prostate cancer. This supports that the treatment of 
diabetes could remove the risk increase associated with hyperglycemia. However, the changes in 
blood glucose level after initiation of antidiabetic drug use during the follow-up was not connected 
to PCa risk, which suggests that the possible antitumor effects of antidiabetic drugs are mediated 
through mechanisms other than blood glucose control. However, confirmation will be needed from 
other studies as confidence intervals were relatively wide in our risk estimates. 
 
The association between blood glucose level and PCa risk is likely to be long-term, because the 
elevated risk was observable also for the fasting blood glucose level measured a decade earlier. This 
suggests that diabetic glucose level could increase the risk of initiation of prostate cancer 
development. To our knowledge this is the first study to examine long-term associations between 
fasting blood glucose and prostate cancer risk. However, we did not observe risk associations by 
HbA1c level, which reflects long-term glucose balance. HbA1c results were available for fewer 
participants than were fasting glucose measurements, thus these analyses were limited by lowered 
statistical power. Nevertheless, this difference between the risk associations between HbA1c and 
fasting glucose suggests that the interaction between blood glucose, insulin and prostate cancer may 
be complex. 
 
Strengths of our study include large population-based cohort and information on blood glucose 
measurements starting from the 1980’s. We were also able to evaluate the effect of antidiabetic drug 
on the risk association through comprehensive national prescription database free of recall bias. 
 
The study also has some limitations. We had no information on lifestyle factors, such as smoking, 
diet or physical activity, which could possible affect prostate cancer risk and cause confounding 
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(28-30). The available information on BMI was also limited. Because of these factors, residual 
confounding is possible. 
 
In conclusion, diabetic fasting blood glucose level is associated with elevated PCa risk in a 
population-based cohort of Finnish men, especially in the setting of systematic PSA-based 
screening. The risk association is long-term, observed a decade in advance of the diagnosis.  Use of 
antidiabetic drugs removes the risk association, supporting the risk lowering effect of these drugs. 
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